SENSE Data Shows DX System is Equivalent to Dual-Chamber ICDs and Superior to Single-Chamber in AHRE Detection

LAKE OSWEGO, Ore., July 22, 2019 /PRNewswire/ -- BIOTRONIK today announced the publication of the SENSE Trial results in the Journal of Cardiovascular Electrophysiology, proving BIOTRONIK's DX system is equivalent to dual-chamber implantable cardioverter defibrillators (ICDs) in detecting atrial high-rate episodes (AHREs). Trial data also demonstrates the DX system is superior to single-chamber ICDs.

"We've proven that the DX system gathers significant data with a single lead. Having the benefits of dual-chamber diagnostics without the need for an atrial lead is a true advantage for electrophysiologists," said Dr. George Thomas, SENSE Primary Investigator, Weill Cornell Medical College, New York. "The system can be trusted to deliver appropriate therapy while providing exceptional diagnostic data that improves patient care and outcomes."

AHREs create an increased risk of developing atrial fibrillation (AF)¹ — when AF is left undetected, patients are at an increased risk of stroke. Typically, atrial sensing capabilities require the need for an additional lead, creating increased risk of complications. BIOTRONIK's DX system, featured in both ICD and cardiac resynchronization therapy defibrillator (CRT-D) devices, detects a true atrial signal without the need for an atrial sensing lead² — reducing costs, procedure complexity and implant time compared to dual-chamber ICDs.^3,4,5

The SENSE Trial analyzed the efficacy of the DX system in detecting AHREs compared to single-chamber ICDs and dual-chamber ICDs. This prospective cohort-controlled trial enrolled 150 patients with a DX system at eight study centers in the U.S. and compared results to retrospective single and dual-chamber age, sex and left ventricular ejection fraction (LVEF) matched cohorts. The AHRE detection rates at 12-months post implant are below:

• DX: 13.0 percent
• Dual-Chamber: 13.0 percent
• Single-Chamber: 5.3 percent

DX patients received zero inappropriate shocks, where traditional single-chamber patients had an inappropriate shock rate of 3.3 percent. Other large studies have reported inappropriate shock rates for single-chamber ICDs as high as 6 percent at one year.⁶ This data provides an additional proof point of DX superiority over single-chamber and demonstrates the system's ability to reduce inappropriate therapy. DX also maintained quality atrial sensing amplitudes from implant to 12-month follow up, aiding in the ability to consistently and appropriately detect AHRE.

"The DX system features the only ICD on the market that provides dual-chamber diagnostics through a single lead based on a true atrial signal. Results of the SENSE Trial further demonstrate the superiority of the DX system," said Ryan Walters, President at BIOTRONIK, Inc. "Early detection, fewer complications and increased peace of mind for patients and physicians — that is exactly what BIOTRONIK's DX system provides."

The SENSE Trial was sponsored by Weill Medical College of Cornell University in cooperation with BIOTRONIK. Further information can be found at clinicaltrials.gov (identifier NCT02186704). The DX system is currently available in BIOTRONIK's recently launched Acticor devices. 

References
¹Healey JS, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120-9.
² Worden N, et al. "Two for the Price of One": A Single-Lead Implantable Cardioverter-Defibrillator System with a Floating Atrial Dipole. J Atr Fibrillation, 2016; 8(6), 1396
³Dewland TA, et al. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol. 2011 Aug 30;58(10):1007-13.
⁴Sticherling C, et al. Comparison of a novel, single-lead atrial sensing system with a dual-chamber implantable cardioverter-defibrillator system in patients without antibradycardia pacing indications: results of a randomized study. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):56-63.
⁵Schuchert A, et al. Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker. Europace. 2013 Jan;15(1):71-6.
⁶Ruwald AC, et al. Frequency of inappropriate therapy in patients implanted with dual- versus single-chamber ICD devices in the ICD arm of MADIT-CRT. J Cardiovasc Electrophysiol. 2013 Jun;24(6):672-9.

About BIOTRONIK
BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. BIOTRONIK has US offices in New York City and Lake Oswego, Oregon.

For more information, visit: www.biotronik.com 
Twitter: @BIOTRONIK_US 
Facebook: facebook.com/BIOTRONIKUS 
LinkedIn: linkedin.com/company/BIOTRONIK 
YouTube: youtube.com/biotronikus

SOURCE BIOTRONIK

Related Links

http://www.biotronik.com